Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Tissue Regenix adds sales specialist for US orthopaedic drive

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.
Tissue Regenix adds sales specialist for US orthopaedic drive
Knee cartilages are expected to be approved by end of 2016

Tissue Regenix (LON:TRX)  has strengthened the management of its US operation with the appointment of Drew Distin to its new orthopaedic subsidiary.

Distin is a specialist in building sales through targeted marketing and has worked for a number of other US companies.

His remit is to plan the launch Tissue Regenix’s new range of orthopaedic products on the US.

Clinical trials are currently ongoing in Europe for OrthoPure XM (porcine meniscus) and OrthoPure XT (porcine tendon) products, with the a target a CE mark for the XM knee cartilage by the end of 2016.

In the US, Tissue will initially focus on  human tissue applications, initially starting with the human tendon (OrthoPure HT).

Tissue Regenix is currently in partnership with tissue bank Community Tissue Services (CTS) for the manufacturing of its wound care product DermaPure.

Peter Hamer, Tissue Regenix Orthopaedic’s commercial director, said Distin brings a wealth of experience.

“This is a very exciting time for Orthopaedics at Tissue Regenix as we continue enrolment of our OrthoPure XT clinical trial and await submission for the CE mark with OrthoPure XM.

“We are on course to complete these tasks within the timeline predicted."

PhilW.jpg


Register here to be notified of future TRX Company articles
View full TRX profile

Tissue Regenix Group PLC Timeline

Related Articles

immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
Pollen2.jpg
Thu
Turnover was £40.4mln in the six months to December

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.